| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802281201019 | 228120101 | RILUTEK F.C.TAB 50MG/TAB BTX56(BLIST4X14) | 78.56 | 82.41 | 104.82 |
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.